A Comparison Between Classification Algorithms for Postmenopausal Osteoporosis Prediction in Tunisian Population

2016 ◽  
pp. 234-248
Author(s):  
Naoual Guannoni ◽  
Rim Sassi ◽  
Walid Bedhiafi ◽  
Mourad Elloumi
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Tunisian Population ◽  
Classification Algorithms

Spectral and Topographic Microstructure of Brain Alpha Activity During Drowsiness at Sleep Onset and REM Sleep

2000 ◽  
Vol 14 (3) ◽  
pp. 151-158 ◽  
Author(s):  
José Luis Cantero ◽  
Mercedes Atienza
Keyword(s):  
Rem Sleep ◽  
Spectral Component ◽  
Sleep Onset ◽  
Quantitative Information ◽  
Maximum Energy ◽  
Alpha Activity ◽  
The Other ◽  
Classification Algorithms ◽  
Microstructural Properties ◽  
Brain States

Abstract High-resolution frequency methods were used to describe the spectral and topographic microstructure of human spontaneous alpha activity in the drowsiness (DR) period at sleep onset and during REM sleep. Electroencephalographic (EEG), electrooculographic (EOG), and electromyographic (EMG) measurements were obtained during sleep in 10 healthy volunteer subjects. Spectral microstructure of alpha activity during DR showed a significant maximum power with respect to REM-alpha bursts for the components in the 9.7-10.9 Hz range, whereas REM-alpha bursts reached their maximum statistical differentiation from the sleep onset alpha activity at the components between 7.8 and 8.6 Hz. Furthermore, the maximum energy over occipital regions appeared in a different spectral component in each brain activation state, namely, 10.1 Hz in drowsiness and 8.6 Hz in REM sleep. These results provide quantitative information for differentiating the drowsiness alpha activity and REM-alpha by studying their microstructural properties. On the other hand, these data suggest that the spectral microstructure of alpha activity during sleep onset and REM sleep could be a useful index to implement in automatic classification algorithms in order to improve the differentiation between the two brain states.

Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

2014 ◽  
Vol 23 (01) ◽  
pp. 49-55
Author(s):  
L. C. Hofbauer ◽  
D. Felsenberg ◽  
M. Amling ◽  
A. Kurth ◽  
P. Hadji
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Osteoporosis ◽  
Primary Outcome ◽  
Osteoporosis Treatment ◽  
Secondary Outcome ◽  
Matched Pairs ◽  
Fracture History ◽  
Baseline Characteristics ◽  
Study Inclusion

SummaryIt is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic postmenopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months.4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects.At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteo - porosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group).The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.

Zoledronate in the treatment of postmenopausal osteoporosis

2007 ◽  
Vol 115 (S 1) ◽  
Author(s):  
H Stracke ◽  
S Wamsler ◽  
A Liebchen ◽  
RG Bretzel
Keyword(s):  
Postmenopausal Osteoporosis

RADIOCALCIUM KINETIC STUDIES AFTER AN OESTROGEN-GESTOGEN COMBINATION IN POSTMENOPAUSAL OSTEOPOROSIS

1971 ◽  
Vol 68 (1_Supplb) ◽  
pp. S80 ◽  
Author(s):  
Angelo Caniggia ◽  
Carlo Gennari
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Kinetic Studies

Farnesylpyrophosphate synthase rs2297480 polymorphism and the response to the zoledronic acid in the treatment of postmenopausal osteoporosis

2014 ◽  
Author(s):  
Svetlana Yureneva ◽  
Oksana Yakushevskaya ◽  
Andrey Donnikov ◽  
Sergey Kuznetzov ◽  
Svetlana Mullambaeva ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Postmenopausal Osteoporosis

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

2014 ◽  
Author(s):  
Fatma Gossiel ◽  
Kim Naylor ◽  
Eugene McCloskey ◽  
Nicola Peel ◽  
Jennifer Walsh ◽  
...  
Keyword(s):  
Postmenopausal Osteoporosis ◽  
Bisphosphonate Treatment
Sign in / Sign up

Export Citation Format

Share Document